Comparative safety of nivolumab plus ipilimumab versus nivolumab plus relatlimab in advanced melanoma: a pharmacovigilance study based on the FDA adverse event reporting system (FAERS)

  1. Shanshan Xu
  2. Zhihui Song
  3. Dong Wang
  4. Ente Wang
  5. Jiawei Wang
Read the full article See related articles

Discuss this preprint

Start a discussion What are Sciety discussions?

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1186/s12885-025-14546-6
  2. Version published to 10.21203/rs.3.rs-6426078/v1 on Research Square